subscribeSubscribe
Ablynx NV`s Cablivi (caplacizumab) Receives Suppl Approval in the U.S.

Ablynx NV`s Cablivi (caplacizumab) Receives Suppl Approval in the U.S.
FDA
11 Apr 2024
Share Share
Cablivi`s Biologic Ablynx (Caplacizumab) Receives Approval in the U.S.

Cablivi`s Biologic Ablynx (Caplacizumab) Receives Approval in the U.S.
FDA
23 Feb 2022
Share Share
NICE green light for Cablivi in rare blood-clotting disorder

NICE green light for Cablivi in rare blood-clotting disorder
Lucy Parsons PHARMATIMES
13 Nov 2020
Share Share
NICE rejects Sanofi`s Cablivi in draft guidelines

NICE rejects Sanofi`s Cablivi in draft guidelines
Selina McKee PHARMATIMES
13 Jun 2020
Share Share
Cablivi® approved by Health Canada for adults living with acquired (aTTP)

Cablivi® approved by Health Canada for adults living with acquired (aTTP)
NEWSWIRE
02 Mar 2020
Share Share
Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment

Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment
PRESS
10 Oct 2019
Share Share
Zeldin joins Immunovant as CMO months after Acceleron split

Zeldin joins Immunovant as CMO months after Acceleron split
Nick Paul Taylor FIERCE BIOTECH
14 Aug 2019
Share Share
Sanofi blood disorder drug wins FDA approval

Sanofi blood disorder drug wins FDA approval
Manogna M REUTERS
07 Feb 2019
Share Share
Ablynx`s Cablivi (Caplacizumab) Receives Supplemental Approval in US

Ablynx`s Cablivi (Caplacizumab) Receives Supplemental Approval in US
FDA
06 Feb 2019
Share Share
FDA approves first therapy for adult patients with rare blood clotting disorder

FDA approves first therapy for adult patients with rare blood clotting disorder
PR NEWSWIRE
06 Feb 2019
Share Share